["{\n\"step_by_step_thinking\": \"There is no mention of ivosidenib or acute myeloid leukemia (AML) in the provided documents. The documents cover various topics such as antineoplastic agents, thromboresistance, antiparkinsonian therapy, pharmacologic approaches to meningeal malignancy, and hematopoietic growth factors like G-CSF and GM-CSF. Therefore, it is not possible to determine FDA approval status of ivosidenib for AML based on these documents.\",\n\"answer_choice\": \"B: no\"\n}"]